Bain Capital Life Sciences Investors
$1.7B 13F equity value
22 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Bain Capital Life Sciences Investors covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| KLRA | KAILERA THERAPEUTICS INC | 22,583,268 | $498M | 29.6% |
| HTFL | HEARTFLOW INC | 8,448,158 | $248M | 14.7% |
| NAMS | NEWAMSTERDAM PHARMA COMPANY | 3,806,566 | $129M | 7.7% |
| SVRA | SAVARA INC | 17,600,621 | $108M | 6.4% |
| ALKS | ALKERMES PLC | 1,937,938 | $102M | 6.0% |
| SLDB | SOLID BIOSCIENCES INC | 9,808,819 | $98M | 5.8% |
| PHVS | PHARVARIS N V | 2,675,509 | $93M | 5.5% |
| OLMA | OLEMA PHARMACEUTICALS INC | 7,085,249 | $89M | 5.3% |
| COAG | HEMAB THERAPEUTICS HOLDINGS INC | 1,650,000 | $61M | 3.6% |
| CABA | CABALETTA BIO INC | 17,241,445 | $54M | 3.2% |
Track Bain Capital Life Sciences Investors's 13F portfolio: $1.7B in reported holdings, 22 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}